Prospera Financial Services Inc Increases Stake in Novo Nordisk A/S $NVO

Prospera Financial Services Inc grew its stake in Novo Nordisk A/S (NYSE:NVO) by 267.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 378,006 shares of the company’s stock after buying an additional 275,104 shares during the quarter. Prospera Financial Services Inc’s holdings in Novo Nordisk A/S were worth $26,091,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S during the first quarter worth $30,000. NewSquare Capital LLC raised its position in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares during the period. Disciplina Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares in the last quarter. Dagco Inc. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S in the 2nd quarter worth about $37,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 1.9%

Shares of NVO opened at $45.62 on Friday. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $112.52. The stock has a market cap of $203.69 billion, a PE ratio of 12.53, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The firm’s fifty day moving average is $55.32 and its two-hundred day moving average is $61.49. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.74 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on NVO shares. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. HSBC set a $70.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, October 1st. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Finally, Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.